<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054999</url>
  </required_header>
  <id_info>
    <org_study_id>18-006247</org_study_id>
    <nct_id>NCT04054999</nct_id>
  </id_info>
  <brief_title>[Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients]</brief_title>
  <official_title>The Efficacy of Intravenous Hydroxocobalamin Versus Methylene Blue as Treatment for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for
      refractory vasoplegic syndrome during liver transplant surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, prospective, open label, pilot study will involve 20 LT patients with
      intraoperative vasoplegic syndrome. If vasoplegic syndrome is identified via SVR lower than
      500 dynes-sec/cm-5, the patients will be randomized to receiving either IV methylene blue or
      hydroxocobalamin (10 patients in each group). The primary end point will examine the efficacy
      of the two medications on treating intraoperative vasoplegic syndrome. The SVR, blood
      pressure, and amount of administered vasopressors at 0, 15, 30, 60, 90, 120, 150, and 180
      minutes after the medication administrations will be recorded. .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Open-Label, pilot study to describe the efficacy of hydroxocobalamin vs methylene blue</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic Vascular Resistance (SVR)</measure>
    <time_frame>Intraoperative period</time_frame>
    <description>Improving hemodynamic stability as measured by SVR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure (BP)</measure>
    <time_frame>Intraoperative period</time_frame>
    <description>Improving hemodynamic stability as measured by systemic blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vasopressors</measure>
    <time_frame>Intraoperative period</time_frame>
    <description>Improving hemodynamic stability as measured by amount of vasopressors administered.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early tracheal extubation</measure>
    <time_frame>up to 1 day after surgery</time_frame>
    <description>Patient outcomes in the postoperative period as measured by early tracheal extubation after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital and intensive care unit stay</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Patient outcomes in the postoperative period as measured by length of hospital and intensive care unit stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative complications</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Patient outcomes in the postoperative period as measured by perioperative complications (stroke, myocardial infarction, and acute renal failure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function</measure>
    <time_frame>Up to 1 year after surgery</time_frame>
    <description>Patient outcomes in the postoperative period as measured by graft function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>Up to 1 year after surgery</time_frame>
    <description>Patient outcomes in the postoperative period as measured by survival rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Vasoplegic Syndrome</condition>
  <condition>Liver Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Cyanokit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose intraoperatively of Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylene Blue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose intraoperatively of Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxocobalamin</intervention_name>
    <description>Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes</description>
    <arm_group_label>Cyanokit</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <description>Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes</description>
    <arm_group_label>Methylene Blue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Patients scheduled to undergo liver transplantation

          -  Patients able to read and understand consent document (if patient is unable to provide
             an informed consent, the Legally Authorized Representative will be ask to consent on
             behalf of the patient).

          -  SVR lower than 500 dynes-sec/cm-5 intraoperatively (this criterion must be met after
             consent intraoperatively)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sher-Lu Pai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sher-Lu Pai, MD</last_name>
    <phone>904-953-2000</phone>
    <email>pai.sherlu@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Sher-Lu Pai</investigator_full_name>
    <investigator_title>Consultant in Anesthesia</investigator_title>
  </responsible_party>
  <keyword>hydroxocobalamin</keyword>
  <keyword>methylene blue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasoplegia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan in place.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

